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the study was conducted under the public health perspective, only direct medical
costs associated with the RSV treatment were evaluated (hospitalization, emer-
gency room, drugs, and prophylaxis). For resource utilisation purposes, an expert
panel of paediatricians with experience in RSV infection was convened. Drug and
medical attention costs were discounted by using a 3% discount rate and are re-
ported in local currency. Acceptability curves of the probability of palivizumab to
be cost effective were calculated. The threshold included in the study for cost-
effectiveness comparisons, is the proposed by the World Health Organisation (3
times the gross domestic product per capita). RESULTS: The ICER per QALY for the
study group was MXN $219,150. The acceptability curves showed a 75% probability
of palivizumab to be cost effective when employing a 3 times GDP threshold.
CONCLUSIONS: The use of palivizumab represents a cost-effective alternative for
the prophylaxis of complications associated with RSV infection, under the public
health perspective in Mexico for patients 29 WGA.
PRS5
COST-EFFECTIVENESS OF VARENICLINE VS EXISTING SMOKING CESSATION
STRATEGIES IN DOMINICAN REPUBLIC USING THE BENESCO MODEL
Lutz M, Morales G, Cuesta G
Pfizer S.A., La Aurora, Heredia, Costa Rica
OBJECTIVES: In Dominican Republic, the economic burden of tobacco has not been
assessed. The aim of this study was to evaluate the cost-effectiveness of vareni-
cline compared to other existing strategies for smoking cessation within a 5-year
time horizon in an adult population cohort from Dominican Republic using the
healthcare payer’s perspective. METHODS: The Benefits of Smoking Cessation on
Outcomes (BENESCO) simulation model was used for an adult cohort in Dominican
Republic (n6,528,125). Smoking cessation therapies compared were: varenicline
(0.5 – 2 mg/day) versus bupropion (300 mg/day); nicotine replacement treatment
(NRT) (5-10 mg/day) and unaided cessation. Effectiveness measures were: Life-Year
gained (LYG) and quality-adjusted life-year gained (QALY’s). Resource use and
costs data were obtained from Dominican Republic’s Ministry of Health and Social
Security databases (2009). The model used a 3% discount rate for costs (expressed
in 2009 US dollars) and health outcomes. Probabilistic sensitivity analyses (PSA)
were conducted and acceptability curves were constructed. RESULTS: Varenicline
reduced smoking-related morbidity, mortality and healthcare costs. After 5 years,
mortality in the varenicline arm was reduced by 67, 86 and 163 deaths compared
with bupropion, NRT and unaided cessation, respectively. The net average cost per
additional quitter showed that varenicline was cost-saving against competing al-
ternatives. Varenicline exhibited 145, 188 and 355 more QALYs against Bupropion,
NRT and unaided cessation, respectively. Cost-effectiveness analyses showed that
varenicline was the dominant strategy. At a willingness-to-pay of US$8,000/QALY,
the probability that varenicline is cost-effective met 100%. PSA results support the
robustness of the findings. CONCLUSIONS: Smoking cessation therapy with va-
renicline is cost-saving in Dominican Republic. These results could help to reduce
the tobacco related disease burden and align cost-containment policies.
PRS6
COST-EFFECTIVENESS OF FLUTICASONE FUROATE COMPARED WITH
MOMETASONA FUROATE FOR THE PRIMARY TREATMENT OF ALLERGIC
RHINITIS PATIENTS
Rely K1, Alexandre PK2, Anaya P3, Salinas GE4
1CEAHealthTech, México, D.F., México, 2Johns Hopkins University, Baltimore, MD, USA,
3GlaxoSmithKline México, México, D.F., México, 4Hospital Infantil de México Federico Gómez,
Secretaría de Salud, México, D.F., México
OBJECTIVES: To evaluate the cost-effectiveness of fluticasone furoate vs. mome-
tasone furoate in the treatment of ocular symptoms in allergic rhinitis patients in
Mexico. METHODS: A decision-analytic model was developed to estimate the cost-
effectiveness of fluticasone furoate versus mometasone furoate. Patients initiated
on treatment either completed initial therapy or switched to second line therapy
due to non-response. Probability of a switch and resource use was based on expert
panel and literature. Costs were based on local drug acquisition costs, local cost
estimates for outpatient and hospitalization. Effectiveness was defined as the net
improvement in Total Ocular Symptom Score (TOSS) at 12 weeks from Keith PK.
2009 study. The analysis was carried out from the perspective of the Mexican
health care system and all costs are reported in 2010 US dollars. RESULTS: The
corresponding health effects were 0.47 net improvement TOSS for fluticaone fu-
roate and 0.31 for mometasone furoate regimen. The mean total cost of the fluti-
caone furoate regimen was $ 627 compared with $ 827 for the furoate mometasone
regimen. Treatment with fluticasone furoate compared to treatment with mome-
tasone furoate was less costly and resulted in a greater net improvement of TOSS.
Probabilistic sensitivity analyses demonstrated that the cost savings observed
were maintained over a wide range of alternative values for costs and resource
utilization. CONCLUSIONS: Cost-effectiveness analysis indicated the dominance
of fluticasone furoate over mometasone furoate because of both lower costs and
greater efficacy. Cost savings with fluticasone furoate were attributable to lower
drug acquisition costs. In addition, a net improvement in ocular symptoms may be
expected in allergic rhinitis patients.
PRS7
ESTUDIO DE COSTO-EFECTIVIDAD DE BECLOMETASONA VS CICLESONIDA
COMO MEDICAMENTOS CONTROLADORES EN EL MANEJO DEL ASMA EN
PACIENTES QUE ASISTEN A CONSULTA EXTERNA DE NEUMOLOGÍA
PEDIÁTRICA EN EL HOSPITAL UNIVERSITARIO CLÍNICA SAN RAFAEL DE
BOGOTÁ COLOMBIA, JULIO A DICIEMBRE 2010
Hinestrosa F1, Pedraza AM2
1Grünenthal Colombiana S.A., Bogotá, Colombia, 2Hospital San Rafael, Bogotá, Colombia
OBJECTIVOS:Desarrollar un estudio de costo-efectividad que compare Ciclesonida
con Beclometasona en el control del asma. METODOLOGÍAS: Estudio Costo-Efec-
tividad, de cohortes, observacional, analítico, con información recolectada pro-
spectivamente, realizado desde la perspectiva institucional, incluyó pacientes
pediátricos con diagnóstico de asma no controlada admitidos durante Julio de 2010
los que recibieron Ciclesonida o Beclometasona como único medicamento contro-
lador. Se realizó seguimiento por 6 meses, basados en datos reportados por la
literatura se utilizó el porcentaje de pacientes libres de crisis asmáticas como vari-
able para el cálculo del tamaño muestral, la muestra necesaria fué de 20 pacientes
por cada alternativa, se incluyeron 94 pacientes con edades entre los 1 y 15 años, 47
recibieron Beclometasona y 47 Ciclesonida. La asignación fue de manera aleatoria.
La variable primaria de efectividad fue definida como el porcentaje de pacientes
libres de crisis durante el periodo de estudio, se definieron como variables genera-
doras de costo uso de medicamentos y estancia hospitalaria. Se calculó la razón
costo-efectividad incremental y se realizó un modelo mediante un árbol de
decisión. RESULTADOS: 17 pacientes estuvieron libres de crisis en el grupo de
Beclometasona, los costos de utilización de medicamentos en este grupo fueron de
$7255.564 pesos colombianos, los costos de hospitalización se calcularon en
$38,568.200, los costos totales ascendieron a $45,823.764 ($25,188.67 dólares). En el
grupo de Ciclesonida, 45 pacientes estuvieron libres de crisis, los costos por uti-
lización de medicamentos fueron de $14,982.172, los costos derivados de hospital-
ización se calcularon en $92,200, los costos totales alcanzaron los $15,074.372
($8291.73 dólares). La razón costo-efectividad incremental de Beclometasona ver-
sus Ciclesonida fue de -1’098.192. CONCLUSIONES: Al utilizar Ciclesonida el hos-
pital encuentra ahorros de $1098.192 pesos por cada paciente libre de crisis, desde
la perspectiva del hospital, el manejar un paciente con Beclometasona representa
un costo adicional de $1,098.192 que se podrían ahorrar si el paciente fuese mane-
jado con Ciclesonida.
PRS8
COST-EFFECTIVENESS OF AN AMBULATORY PROGRAM OF PULMONARY
REHABILITATION FOLLOWING ACUTE EXACERBATIONS OF COPD IN COLOMBIA
Giraldo LF, Brito KP, Rodriguez P
Universidad de La Sabana, Chia, Cundinamarca, Colombia
OBJECTIVES: To evaluate the economic benefits of an 8 week Ambulatory Pulmo-
nary Rehabilitation Program (PR) plus GOLD based standard treatment (ST) vs. ST
without PR of COPD patients after an acute exacerbation of the disease in the
Colombian Health Care System (CHCS). METHODS: Direct costs of ST and of PR
were calculated according to tertiary level university hospital’s registries during
one year and CHCS’s drugs prices; these costs and QALY were estimated for one
year by a Markov chain model based on Seymour’s study (Thorax, 2010) findings of
health care utilization and probability of death. Univariate sensitivity and proba-
bilistic analysis were performed by Monte Carlo method.RESULTS: Following acute
exacerbation of COPD the annual cost of PR plus ST was COL$ 4,594,407,00 (US$
2,483.46) vs. an annual cost of ST without PR of COL$ 9,124,326.00 (US$ 4,932.07).
QALY of PR plus ST patients: 0.86577; QALY of ST without PR: 0.852979. Mean
cost-effectiveness of PR plus ST: COL$5,306,729.00 (US$ 2,868.50) per QALY, cost-
effectiveness of ST without PR:$10,697,014.00 (US$ 5,782.17) per QALY. There was
absolute dominance of PR plus ST vs. ST without PR in all scenarios. In the sensi-
tivity analysis the absolute dominance is maintained for any cost of PR program
COL$ 5,302,428.00 (US$ 2.866,18). CONCLUSIONS: Global costs of Pulmonary Reha-
bilitation plus Standard Treatment are much lower than Standard Treatment with-
out Pulmonary Rehabilitation for patients after an acute exacerbation of COPD.
Pulmonary Rehabilitation is a highly cost-effective treatment for these patients in
the CHCS and probably in many other countries with similar socio-economic level,
specially of Latin America.
Respiratory-Related Disorders – Patient-Reported Outcomes & Preference-Based
Studies
PRS9
DISPONIBILIDAD A PAGAR POR UN METODO EFECTIVO PARA DEJAR DE FUMAR:
EVIDENCIAS A PARTIR DE LA ENCUESTA GLOBAL DE TABAQUISMO EN
ADULTOS MÉXICO 2009
Heredia I, Serván E, Reynales LM, Bautista S
Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México
OBJECTIVOS: Estimar la máxima disponibilidad a pagar (DAP) por un tratamiento
efectivo de cesación tabáquica entre fumadores mexicanos e identificar los facto-
res sociodemográficos, de la historia de fumador y de su entorno asociados a esta
valoración. METODOLOGÍAS: Se realizó un estudio observacional de tipo transver-
sal. La muestra de análisis estuvo constituida por 777 fumadores que participaron
en la Encuesta Global de Tabaquismo en Adultos, México 2009. Se realizó un análi-
sis descriptivo y de asociación estadística que permitió caracterizar a los fuma-
dores y su DAP con base en variables socioeconómicas, demográficas, de su historia
de tabaquismo y de su entorno. RESULTADOS: El 74.4% de los fumadores eran del
sexo masculino, 51.4% consumía cigarrillos con una frecuencia diaria. Los fuma-
dores tenían más de 15 años fumando, 58.6% había realizado intentos previos de
cesación y alrededor del 10% conocía de la existencia de centros de ayuda para
dejar de fumar. En promedio, la DAP por un método efectivo de cesación fue $2573
pesos mexicanos. En los hombres, la DAP fue 2056 pesos menor que en las mujeres.
A mayor educación y mayor nivel socioeconómico (NSE), la DAP de los fumadores
aumentó en todos los modelos estimados. CONCLUSIONES: Las estimaciones del
presente estudio sugieren que los fumadores mexicanos que desean dejar de fu-
mar revelan, en términos monetarios, una alta valoración por un método de ce-
sación efectivo. Los fumadores del sexo masculino muestran un comportamiento
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más “egoísta” que las mujeres fumadoras. En México, se requiere de la implemen-
tación de un mayor número de acciones encaminadas a apoyar a los fumadores en
su intento por abandonar la adicción al tabaco, fortaleciendo y ampliando la oferta
de programas de cesación, así como el acceso a los tratamientos farmacológicos
logrando una cobertura universal mediante la incorporación de las diferentes al-
ternativas farmacológicas al cuadro básico de medicamentos del sector salud.
Sensory Systems Disorders – Cost Studies
PSS1
EVALUACION ECONOMICA DE FOTOTERAPIA DE BANDA ANGOSTA O
FOTOQUIMIOTERAPIA PARA EL TRATAMIENTO DE PSORIASIS DESDE LA
PERSPECTIVA DEL INSTITUTO MEXICANO DEL SEGURO SOCIAL
Carlos F1, Ramos E1, Llorens F2, Ruiz L2
1R A C Salud Consultores, S.A. de C.V., México, D.F., México, 2Tecnologicos Dalup S. De R.L. De
C.V., México, D.F., México
OBJECTIVOS: La psoriasis es una enfermedad cutánea que en sus formas modera-
das-graves afecta la expectativa y calidad de vida. El objetivo fue evaluar costos y
desenlaces en salud de diversas modalidades de tratamiento de psoriasis de grado
moderado-severo desde la perspectiva del Instituto Mexicano del Seguro Social
(IMSS). METODOLOGÍAS: En un modelo Markov se compararon: fototerapia de luz
ultravioleta de banda angosta (UVB-NB); fotoquimioterapia PUVA; metotrexato
(MTX); ciclosporina (CsA); infliximab (INF); etanercept (ETA); adalimumab (ADA). Se
contemplaron dos horizontes temporales: período de evaluación (12-16 semanas)
seguido de un período de 10 años donde los respondedores continúan tratamiento.
Cada ciclo anual los pacientes enfrentan riesgo de muerte y de abandono por
pérdida de eficacia o por eventos adversos. Se analizaron los costos de adquisición
y administración de terapias, monitoreo de pacientes y costo adicional por falla
terapéutica. Mediante revisión sistemática se identificó el cambio en el puntaje
PASI (Psoriasis Area Severity Index) asociado con cada estrategia y su efecto en
calidad de vida. Los costos se expresan en pesos mexicanos (MXN) 2010.
RESULTADOS: El costo total acumulado por paciente es más bajo cuando se utiliza
PUVA ($589,636); MTX ($602,045) o UVB-NB ($602,749) que cuando se emplea CsA
($644,268) o algún agente biológico: $919,292 (ETA); $1,048,781 (ADA) y $1,190,837
(INF). La mejor respuesta se obtuvo con ADA e INF. El costo más bajo por categoría
de respuesta (moderada o buena) se encontró con PUVA, seguido de UVB-NB, MTX
y CsA. En todos los casos, los agentes biológicos condujeron a un costo por re-
spuesta notablemente más elevado. UVB-NB y PUVA fueron dominantes (menos
costosos y con más años de vida ajustados por calidad) con relación a MTX, CsA y
ETA. CONCLUSIONES: UVB-NB y PUVA representan las alternativas más costo-
efectivas y potencialmente costo-ahorradoras al compararse con otras modali-
dades de tratamiento utilizadas actualmente en IMSS.
PSS2
ENCOURAGING THE EFFICIENCY OF THE NATIONAL TRANSPLANT PROGRAM:
ESTIMATING THE COST OF CORNEAL TRANSPLANT TO BE FINANCED BY
PUBLIC INSTITUTIONS IN THE HEALTH SECTOR IN MEXICO
Camacho A, Gutierrez C
Mexican Ministry of Health, México, D.F. México
OBJECTIVES: Estimate the cost of procurement-surgery-follow up for corneal
transplant to be covered by public institutions in Mexico, in the context of the
National Transplant Program. The estimation is important, because according to
economic evaluation studies in Mexico, corneal transplant is considered a very cost
effective intervention. However, there is a considerable list of patients awaiting
corneal transplant. This situation urges forward the Ministry of Health to analyze
the various aspects involved in the corneal procurement-transplant process.
METHODS: A micro-costing was developed considering the clinical treatment pro-
tocol developed by the collegiate body of the General Health Council of Mexico. The
protocol includes three phases: preoperative, surgery and follow-up. Each phase
requires a number of studies, medical supplies, medicines and medical staff. The
unit cost of required inputs are obtained from the public health sector. RESULTS:
The total cost of the procurement-surgery-follow up of corneal transplant, was
US$2037. The phase that represents the lowest percentage of total cost is the pre-
operative (13.4%), the greatest cost comes in the stage of surgery with US$1042
(46.4%). This stage includes the most expensive supply (trephine) as well as the cost
of the procurement process. Finally, the follow up phase amounts to US$722 which
represents the cost of medical visits and drug therapy for one year.CONCLUSIONS:
The results allow estimating the total cost of corneal transplant in the context of
public institutions in Mexico. This estimate provides vital information for the de-
cision making process of developing sustainable strategies for the abatement of the
list of patients waiting for corneal transplantation.
PSS3
UN ESTUDIO DE COSTO-EFECTIVIDAD PARA EVALUAR EL TRATAMIENTO CON
N-ACETIL CISTEÍNA EN PACIENTES CON ESCLEROSIS SISTÉMICA
Lopez JA1, Briones B2
1Sandoz México, México, D.F., México, 2Novartis Farmaceutica, México, D.F., México
OBJECTIVOS: La terapia con N-Acetil Cisteína ha demostrado ser eficaz y segura en
pacientes con Esclerosis Sistémica (ES). El objetivo de este análisis es comprobar la
costo-efectividad de la adición de N-Acetil Cisteína al tratamiento estándar para
ES. METODOLOGÍAS: Este es un estudio de costo-efectividad desde la perspectiva
institucional del Instituto Mexicano del Seguro Social (IMSS). Se evaluó el trata-
miento estándar a base de prednisona 10 mg/d y penicilamina 300 mg/d en com-
paración con el mismo tratamiento más la adición de N-Acetil Cisteína 1.8 g/d
durante seis meses. La medición de eficacia utilizada fue la mejora en capacidad
vital (CV), medida por espirometría; los datos de eficacia fueron obtenidos de estu-
dios publicados. Los costos y la utilización de recursos fueron obtenidos de la
institución; todos los costos están expresados en Pesos Mexicanos y son vigentes
para el 2010. El horizonte temporal fue de 6 meses, por lo cual no se utilizó tasa de
descuento. Se realizó un análisis probabilístico de sensibilidad a través de una
simulación de Monte Carlo con 100,000 iteraciones para corroborar la robustez del
modelo. RESULTADOS: El análisis reveló un índice de costo-efectividad de $9898.74
para el grupo que recibió el tratamiento estándar más la adición de N-Acetil
Cisteína, en comparación con un índice de $7158.09 para el grupo que sólo recibió
el tratamiento estándar, lo cual nos da como resultado un índice incremental de
costo-efectividad de $2740.65, que es el costo por cada unidad adicional de eficacia
con la adición del tratamiento de N-Acetil Cisteína. CONCLUSIONES: La adición de
N-Acetil Cisteína al manejo de pacientes con ES supone un incremento en la efica-
cia y una mejora en la capacidad vital, que conlleva un costo adicional de $2740.65
por cada unidad adicional de eficacia, convirtiendo a N-Acetil Cisteína en un trata-
miento costo-efectivo.
Sensory Systems Disorders – Patient-Reported Outcomes & Preference-Based
Studies
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DEVELOPMENT OF A QUESTIONNAIRE ASSESSING THE BURDEN OF
ICHTHYOSIS IN INFANTS
Taieb C1, Dufresne H2, Bodemer C2
1PFSA, Boulogne Billancourt, France, 2Hopital Necker, Paris, France
OBJECTIVES: To explore the handicap, in the largest sense, generated by ichthyosis
using a questionnaire to express the burden of the illness on the daily life of pa-
tients and their family, in order to anticipate and treat it more effectively.
METHODS: The questionnaire was developed following a strict methodological
process involving a multidisciplinary team incorporating various players (doctors,
nurses, social workers) who are involved in the treatment of patients and caring for
their families in order to guarantee its credibility and reliability. A review of the
literature and discussions with the children and their families were conducted in
order to identify the concepts related to the pathology. RESULTS: Exploratory as-
sessments showed that the concept of burden could be structured around 5 com-
ponents: feeling of pain, daily life, family and personal relationships, work and
psychological impact. 96 preliminary items were identified at the end of the first
discussion. A first analysis managed to reduce these items to 40 whilst conserving
the 5 components but making it easier to use the analysis. The creation of a “child
module” aimed at children who are able to provide answers independently proved
necessary. CONCLUSIONS: Chronic pathologies such as ichthyosis, which remains
a rare and incapacitating illness, are difficult to assess by clinical or quality of life
aspects alone as their impact can be multidimensional. Although there is no spe-
cific quality of life questionnaire, several existing questionnaires attempt to assess
one or other of these components; our questionnaire entitled “Family Burden Ich-
thyosis” takes them all into consideration in order to explain every angle of the
handicap generated.
Systemic Disorders/Conditions – Cost Studies
PSY1
EPIDEMIOLOGY AND SOCIOECONOMIC BURDEN OF OVERWEIGHT AND
OBESITY IN ARGENTINA
Elgart JF, Gonzalez L, Caporale JE, Pfirter G, Gagliardino JJ
CENEXA - Centro de Endocrinología Experimental y Aplicada (UNLP-CONICET La Plata, Centro
Colaborador OPS/OMS), La Plata, Buenos Aires, Argentina
OBJECTIVES: Obesity is a global epidemic with a heavy socio-economic burden.
This study estimates such burden in Argentina and provides useful evidence to
design prevention, control and treatment strategies for obesity and other cardio-
vascular risk factors (CVRFs). METHODS: Descriptive statistical analyses of the
National Survey of Risk Factors (2005) to identify associations between overweight/
obesity (classified according to BMI values and WHO criteria) and demographic/
epidemiological characteristics. It estimates fatal events, cost of premature deaths
(human capital approach) and loss of healthy life years due to overweight and
obesity. Differences in means and proportions were verified using Student’s t test,
ANOVA and Chi2. RESULTS: The national prevalence of overweight and obesity
was 34.8% and 14.8%, respectively; age range of the adult overweight/obesity pop-
ulation was 35-64 years; obese people were older than normal weight and over-
weight (49.4 vs. 38.7 and 47.3, respectively); 16.2% of the obese people had unsat-
isfied basic needs (15.1% in overweight people). Prevalence of obesity (15.2%) was
lower than that of overweight (21.6%) in university students. Obesity was fre-
quently associated with other CVRFs, being hypertension the most frequent one
(48.1%). The association with two o more CVRFs was greater in obese than in over-
weight people (23.3% vs. 16.6%), with 14.776 deaths due to overweight/obesity. The
statistical value of life in Argentina was $39,174. The cost attributable to premature
deaths due to obesity/overweight was $190.5 millions (70% due to overweight). We
estimate 596.704 lost healthy life years due to overweight/obesity. CONCLUSIONS:
Implementation of effective strategies for the prevention and treatment of over-
weight and obesity is necessary to decrease their high socioeconomic costs and
their negative impact upon lost healthy life years.
PSY2
ESTIMACIÓN DEL IMPACTO FINANCIERO EN LA SALUD DE LA POBLACIÓN
MEXICANA DERIVADO DE LA OBESIDAD Y EL SOBREPESO, 2000-2017
Guajardo-Barron VJ, Gutierrez-Delgado MC
Mexican Ministry of Health, México, D.F., México
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